Real-world one year outcomes of a switch to aflibercept from ranibizumab in neovascular age related macular degeneration

被引：0
|
作者：
Citu, Maria Cristina [1 ,2 ]
Crosby-Nwaobi, Roxanne R. [1 ,2 ]
Eleftheriadou, Maria [1 ,2 ]
Vazquez-Alfageme, Clara [1 ,2 ]
Nicholson, Luke [1 ,2 ]
Sivaprasad, Sobha [1 ,2 ]
Hykin, Philip [1 ,2 ]
Hamilton, Robin D. [1 ,2 ]
机构：
[1] Moorfields Eye Hosp, NIHR Biomed Res Ctr, London, England
[2] UCL, Inst Ophthalmol, London, England
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2016年 / 57卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
3342
引用
收藏
页数：3
相关论文
共 50 条
  • [1] 4 YEAR REAL-WORLD OUTCOMES OF RANIBIZUMAB TREATMENT FOR NEOVASCULAR AGE RELATED MACULAR DEGENERATION
    Chew, Jamie
    Broadhead, Geoffrey
    Li, Haitao
    Chang, Andrew
    [J]. CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2012, 40 : 107 - 107
  • [2] Real-world UK NHS outcomes of a switch to Aflicercept from Ranibizumab in Neovascular age related macular degeneration (nvAMD)
    Citu, Maria Cristina
    Crosby-Nwaobi, Roxanne R.
    Hykin, Philip G.
    Hamilton, Robin
    Sivaprasad, Sobha
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [3] Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration
    Brynskov, Troels
    Munch, Inger Christine
    Larsen, Tobias Malte
    Erngaard, Iiv
    Sorensen, Torben Lykke
    [J]. ACTA OPHTHALMOLOGICA, 2020, 98 (02) : 132 - 138
  • [4] Measuring real-world visual acuity outcomes for ranibizumab and aflibercept in treatment of neovascular age-related macular degeneration (nAMD)
    Karamat, Ayesha
    O'Neill, Charles
    Corradetti, Giulia
    Lindenberg, Sophiana
    Tojjar, Jasaman
    Almidani, Louay
    Do, Giang
    Mauger, Stephanie
    Nittala, Muneeswar
    Chauhan, Devinder
    Sadda, SriniVas
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [5] One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age related macular degeneration
    Almuhtaseb, H.
    Kanavati, S.
    Rufai, S. R.
    Lotery, A. J.
    [J]. EYE, 2017, 31 (06) : 878 - 883
  • [6] Two Year Real World Outcomes of Ranibizumab Therapy for Neovascular Age Related Macular Degeneration (nAMD)
    Bhalla, Minak
    Muniraju, Ramu
    [J]. OPHTHALMOLOGICA, 2014, 232 : 4 - 4
  • [7] Effectiveness of Continued Ranibizumab Therapy in Neovascular Age-Related Macular Degeneration versus Switch to Aflibercept: Real World Evidence
    Chakravarthy, Usha
    Bezlyak, Vladimir
    Sagkriotis, Alexandros
    Griner, Ray
    Skelly, Adrian
    Boyer, David S.
    Milnes, Fran
    [J]. OPHTHALMOLOGY RETINA, 2019, 3 (01): : 8 - +
  • [8] METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Kim, Leah N.
    Mehta, Hemal
    Barthelmes, Daniel
    Vuong Nguyen
    Gillies, Mark C.
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2016, 36 (08): : 1418 - 1431
  • [9] One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration
    H Almuhtaseb
    S Kanavati
    S R Rufai
    A J Lotery
    [J]. Eye, 2017, 31 : 878 - 883
  • [10] Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
    Chang, Yi-Sheng
    Lee, Wan-Ju
    Lim, Chen-Chee
    Wang, Shih-Hao
    Hsu, Sheng-Min
    Chen, Yi-Chian
    Cheng, Chia-Yi
    Teng, Yu-Ti
    Huang, Yi-Hsun
    Lai, Chun-Chieh
    Tseng, Sung-Huei
    [J]. SCIENTIFIC REPORTS, 2018, 8
12345